Nasdaq · Healthcare
Wave Life Sciences Ltd. (WVE)
As-reported financials and recent SEC filings for Wave Life Sciences Ltd., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$42.7M
Net income
$-204.4M
Net margin
—
Diluted EPS
$-1.21
ROE
-39.4%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $42.7M | $108.3M | $113.3M | $3.6M | $41.0M |
| Gross profit | — | — | — | — | — |
| Operating income | $-215.4M | $-110.4M | $-68.0M | $-162.7M | $-127.0M |
| Net income | $-204.4M | $-97.0M | $-57.5M | $-161.8M | $-122.2M |
| Diluted EPS | $-1.21 | $-0.70 | $-0.54 | $-2.05 | $-2.36 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-26
View on EDGAR →8-K2026-05-18
View on EDGAR →SCHEDULE 13G/A2026-05-13
View on EDGAR →DEF 14A2026-05-07
View on EDGAR →SCHEDULE 13G/A2026-05-06
View on EDGAR →PRER14A2026-05-01
View on EDGAR →10-K/A2026-04-30
View on EDGAR →10-Q2026-04-28
View on EDGAR →Largest Healthcare peers
Go deeper on WVE
Search Wave Life Sciences Ltd.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.